Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-benzazepine MeSH Supplementary Concept Data 2025


MeSH Supplementary
3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-benzazepine
Unique ID
C479684
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C479684
Entry Term(s)
SB 414796
SB-414796
SB414796
Pharm Action
Dopamine Antagonists
Registry Numbers
0
Heading Mapped to
*Benzazepines
*Sulfones
Frequency
1
Note
a dopamine D3 receptor antagonist; SB-414796 is the (trans)-isomer; structure in first source
Source
J Med Chem 2003 Nov 6;46(23):4952-64
Date of Entry
2003/12/16
Revision Date
2015/08/08
3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-benzazepine Preferred
SB 414796 Narrower
page delivered in 0.002s